The University of Chicago Header Logo

Randy Sweis

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.

    Collapse Research 
    Collapse research activities and funding
    K08CA234392     (SWEIS, RANDY F.)Sep 10, 2018 - Aug 31, 2022
    NIH
    Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
    Role: Principal Investigator

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Huang D, Lynch C, Serra LM, Sweis RF, Chang PJ, Stadler WM, Szmulewitz RZ, O'Donnell PH, Sidana A, Eggener SE, Shalhav AL, Liauw SL, Pitroda SP. Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879. PMID: 39529961; PMCID: PMC11551534.
      Citations:    
    2. Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Sep 19. PMID: 39298147; PMCID: PMC11413753.
      Citations:    Fields:    
    3. Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2024 Sep 15. PMID: 39282902.
      Citations:    Fields:    
    4. Sweis RF. STING activators in cancer care. Clin Adv Hematol Oncol. 2024 Sep; 22(7):331-333. PMID: 39110661.
      Citations:    Fields:    Translation:Humans
    5. Wang Y, Bergman DR, Trujillo E, Fernald AA, Li L, Pearson AT, Sweis RF, Jackson TL. Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy. Cancers (Basel). 2024 Aug 23; 16(17). PMID: 39272799; PMCID: PMC11394213.
      Citations:    
    6. Desai KB, Serritella AV, Stadler WM, O'Donnell PH, Sweis RF, Szmulewitz RZ. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392. PMID: 38536082; PMCID: PMC11147727.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    7. Lee CH, Yogesh Shah A, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Gironés Sarrió R, Lee Cohn A, Asim Bilen M, Gunnestad Ribe S, Krohn Tennøe Ø, Richards D, Sweis RF, Courtright J, Heinrich D, Perini R, Kubiak P, Bock D, Okpara CE, Motzer RJ. Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. Eur Urol. 2024 Nov; 86(5):470-473. PMID: 38777648.
      Citations:    Fields:    
    8. Ziblat A, Horton BL, Higgs EF, Hatogai K, Martinez A, Shapiro JW, Kim DEC, Zha Y, Sweis RF, Gajewski TF. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141. PMID: 38656869; PMCID: PMC11229087.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    9. Bergman DR, Wang Y, Trujillo E, Fernald AA, Li L, Pearson AT, Sweis RF, Jackson TL. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019. PMID: 38515743; PMCID: PMC10954792.
      Citations: 2     Fields:    Translation:HumansCells
    10. Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, Sweis RF, Chamberlain M, Rini BI. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184. PMID: 38372949.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16. PMID: 38394781.
      Citations: 8     Fields:    Translation:Humans
    12. Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1. PMID: 38228414.
      Citations:    Fields:    Translation:Humans
    13. Routy B, Jackson T, Mählmann L, Baumgartner CK, Blaser M, Byrd A, Corvaia N, Couts K, Davar D, Derosa L, Hang HC, Hospers G, Isaksen M, Kroemer G, Malard F, McCoy KD, Meisel M, Pal S, Ronai Z, Segal E, Sepich-Poore GD, Shaikh F, Sweis RF, Trinchieri G, van den Brink M, Weersma RK, Whiteson K, Zhao L, McQuade J, Zarour H, Zitvogel L. Melanoma and microbiota: Current understanding and future directions. Cancer Cell. 2024 01 08; 42(1):16-34. PMID: 38157864; PMCID: PMC11096984.
      Citations: 6     Fields:    Translation:Humans
    14. Wang Y, Bergman DR, Trujillo E, Pearson AT, Sweis RF, Jackson TL. Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms. Sci Rep. 2023 12 18; 13(1):22541. PMID: 38110479; PMCID: PMC10728095.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    15. Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2024 Aug; 7(4):933-943. PMID: 38105142.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    16. Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, Dubensky TW, McWhirter SM, Müller T, Nair N, Luke JJ. Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2023 06 13; 29(12):2336. PMID: 37309603.
      Citations:    Fields:    
    17. Hines JB, Kacew AJ, Sweis RF. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Curr Oncol Rep. 2023 03; 25(3):189-199. PMID: 36705879; PMCID: PMC10994474.
      Citations: 27     Fields:    Translation:Humans
    18. Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S, Stradella A, Müller T. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023 01 04; 29(1):110-121. PMID: 36282874; PMCID: PMC11188043.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    19. Bergman D, Sweis RF, Pearson AT, Nazari F, Jackson TL. A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues. iScience. 2022 Jun 17; 25(6):104387. PMID: 35637730; PMCID: PMC9142654.
      Citations: 4     
    20. Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF, Boni V. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029. PMID: 35165101; PMCID: PMC9365353.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    21. Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE, McGee HM, Rudqvist NP, Spencer CN, Sweis RF, Vincent BG, Wennerberg E, Yuan J, Zappasodi R, Lucey VMH, Wells DK, LaVallee T, Monette A. Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunol Res. 2022 04 01; 10(4):372-383. PMID: 35362046; PMCID: PMC9381103.
      Citations: 34     Fields:    Translation:Humans
    22. Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Nair N, Luke JJ, Müller T. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688. PMID: 34716197.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    23. Walia AS, Sweis RF, Agarwal PK, Kader AK, Modi PK. Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review. Cancers (Basel). 2021 Dec 24; 14(1). PMID: 35008237; PMCID: PMC8750958.
      Citations: 2     
    24. Rouhani SJ, Trujillo JA, Pyzer AR, Yu J, Fessler J, Cabanov A, Higgs EF, Cron KR, Zha Y, Lu Y, Bloodworth JC, Abasiyanik MF, Okrah S, Flood BA, Hatogai K, Leung MY, Pezeshk A, Kozloff L, Reschke R, Strohbehn GW, Chervin CS, Kumar M, Schrantz S, Madariaga ML, Beavis KG, Yeo KJ, Sweis RF, Segal J, Tay S, Izumchenko E, Mueller J, Chen LS, Gajewski TF. Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction. Res Sq. 2021 Nov 24. PMID: 34845442; PMCID: PMC8629200.
      Citations: 3     
    25. Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Shaffer DR, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Richards D, Sweis RF, Courtright J, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ, Pinto A, Girones Sarrio R, Tennøe ØK, Heinrich D. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958. PMID: 34143969; PMCID: PMC8316679.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    26. Okuneye K, Bergman D, Bloodworth JC, Pearson AT, Sweis RF, Jackson TL. A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer. Comput Syst Oncol. 2021 Jun; 1(2). PMID: 34984415; PMCID: PMC8722426.
      Citations: 8     
    27. Richard G, De Groot AS, Steinberg GD, Garcia TI, Kacew A, Ardito M, Martin WD, Berdugo G, Princiotta MF, Balar AV, Sweis RF. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep. 2021 05 11; 11(1):9983. PMID: 33976291; PMCID: PMC8113358.
      Citations: 4     Fields:    Translation:Humans
    28. Quandt J, Arnovitz S, Haghi L, Woehlk J, Mohsin A, Okoreeh M, Mathur PS, Emmanuel AO, Osman A, Krishnan M, Morin SB, Pearson AT, Sweis RF, Pekow J, Weber CR, Khazaie K, Gounari F. Wnt-ß-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol. 2021 04; 22(4):471-484. PMID: 33664518; PMCID: PMC8262575.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    29. Sayaman RW, Saad M, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Ziv E, Bedognetti D, Thorsson V, Galon J. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8. PMID: 33567262; PMCID: PMC8414660.
      Citations: 76     Fields:    Translation:HumansCells
    30. Kacew A, Sweis RF. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258. PMID: 33224141; PMCID: PMC7674585.
      Citations: 38     Fields:    Translation:HumansAnimals
    31. Han L, Gallan AJ, Steinberg GD, Sweis RF, Paner GP. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61. PMID: 32987034; PMCID: PMC7746505.
      Citations: 3     Fields:    Translation:Humans
    32. Andolfi C, Bloodworth JC, Papachristos A, Sweis RF. The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness. Bladder Cancer. 2020 Sep 21; 6(3):225-235. PMID: 33195783; PMCID: PMC7605348.
      Citations: 14     
    33. Hatogai K, Sweis RF. The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290. PMID: 34185299; PMCID: PMC8345230.
      Citations: 13     Fields:    Translation:HumansCells
    34. Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798. PMID: 31670753; PMCID: PMC8211913.
      Citations: 5     Fields:    Translation:Humans
    35. Sweis RF. Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137. PMID: 32122541; PMCID: PMC7521381.
      Citations: 2     Fields:    Translation:Humans
    36. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Group, Galon J, Thórsson V, De Maria A, Nisticò P. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. PMID: 31272507; PMCID: PMC6610889.
      Citations: 5     Fields:    
    37. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Group, Galon J, Thórsson V, De Maria A, Nisticò P. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. PMID: 31113486; PMCID: PMC6529999.
      Citations: 47     Fields:    Translation:HumansAnimals
    38. Pearson AT, Sweis RF. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncol. 2019 05 01; 5(5):743. PMID: 30896751.
      Citations: 6     Fields:    Translation:Humans
    39. Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66. PMID: 30857555; PMCID: PMC6413449.
      Citations: 40     Fields:    Translation:Humans
    40. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083. PMID: 30635339; PMCID: PMC6522301.
      Citations: 323     Fields:    Translation:HumansCells
    41. Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM. Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. JCO Precis Oncol. 2018 Nov; 2:1-7. PMID: 35135165.
      Citations: 12     Fields:    
    42. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      Citations: 2     Fields:    Translation:Humans
    43. Trujillo JA, Sweis RF, Bao R, Luke JJ. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000. PMID: 30181337; PMCID: PMC6145135.
      Citations: 199     Fields:    Translation:HumansAnimalsCells
    44. Drazer MW, Sweis RF. Low clinical adoption of tumor genomic profiling: cause for concern? J Med Econ. 2018 Jul; 21(7):721-723. PMID: 29708449; PMCID: PMC6062854.
      Citations:    Fields:    Translation:Humans
    45. Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. PMID: 29618376; PMCID: PMC5883337.
      Citations: 7     Fields:    Translation:HumansCells
    46. Sanagapalli S, Emmanuel A, Leong R, Kerr S, Lovat L, Haidry R, Banks M, Graham D, Raeburn A, Zarate-Lopez N, Sweis R. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018 Mar 15. PMID: 29542847.
      Citations: 6     Fields:    
    47. Sweis RF, Luke JJ. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017 Jun; 120:1-9. PMID: 28323141; PMCID: PMC5419683.
      Citations: 16     Fields:    Translation:HumansAnimals
    48. Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565. PMID: 27836246; PMCID: PMC5709811.
      Citations: 20     Fields:    Translation:HumansCells
    49. Sweis RF, Ratain MJ. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260. PMID: 28056195.
      Citations:    Fields:    Translation:Humans
    50. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. PMID: 27634566; PMCID: PMC5315677.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    51. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8. PMID: 27197067; PMCID: PMC4943758.
      Citations: 194     Fields:    Translation:HumansCells
    52. Sweis RF, Ratain MJ. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3. PMID: 27138578.
      Citations:    Fields:    Translation:Humans
    53. Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016 Feb 26; 8(2):e513. PMID: 27026837; PMCID: PMC4807912.
      Citations: 14     
    54. Sweis RF, Drazer MW, Ratain MJ. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74. PMID: 26668350; PMCID: PMC4872035.
      Citations: 14     Fields:    Translation:Humans
    55. Chopra V, Govindan S, Kuhn L, Ratz D, Sweis RF, Melin N, Thompson R, Tolan A, Barron J, Saint S. Do clinicians know which of their patients have central venous catheters?: a multicenter observational study. Ann Intern Med. 2014 Oct 21; 161(8):562-7. PMID: 25329204; PMCID: PMC4997807.
      Citations: 13     Fields:    Translation:Humans
    56. Sweis R, Kaufman E, Anggiansah A, Wong T, Dettmar P, Fried M, Schwizer W, Avvari RK, Pal A, Fox M. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther. 2013 Jun; 37(11):1093-102. PMID: 23600790.
      Citations: 17     Fields:    Translation:Humans
    57. Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104. PMID: 23056240; PMCID: PMC3464251.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    58. Sweis RF, Propes MJ, Hyjek E. Actinomyces-induced inflammatory pseudotumor of the lymph node mimicking scrofula. Ann Intern Med. 2011 Jul 05; 155(1):66-7. PMID: 21727298.
      Citations: 1     Fields:    Translation:HumansCells
    59. Sweis RF, Schramm MP, Kozmin SA. Silver-catalyzed [2 + 2] cycloadditions of siloxy alkynes. J Am Chem Soc. 2004 Jun 23; 126(24):7442-3. PMID: 15198582.
      Citations: 19     Fields:    Translation:Cells
    60. Denmark SE, Sweis RF. Fluoride-free cross-coupling of organosilanols. J Am Chem Soc. 2001 Jul 04; 123(26):6439-40. PMID: 11427080.
      Citations: 18     Fields:    
    Sweis's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (224)
    Explore
    _
    Co-Authors (34)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _